Johnson & Johnson (JNJ) Shares Sold by Kanawha Capital Management LLC

Kanawha Capital Management LLC decreased its stake in shares of Johnson & Johnson (NYSE:JNJ) by 1.0% during the 3rd quarter, HoldingsChannel reports. The institutional investor owned 143,476 shares of the company’s stock after selling 1,505 shares during the period. Johnson & Johnson makes up 2.9% of Kanawha Capital Management LLC’s holdings, making the stock its biggest holding. Kanawha Capital Management LLC’s holdings in Johnson & Johnson were worth $18,653,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. Harding Loevner LP acquired a new stake in shares of Johnson & Johnson in the 2nd quarter valued at approximately $106,000. Mitsubishi UFJ Securities Holdings Co. Ltd. raised its position in shares of Johnson & Johnson by 29.9% in the 2nd quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 870 shares of the company’s stock valued at $115,000 after acquiring an additional 200 shares during the period. Lenox Wealth Advisors Inc. raised its position in shares of Johnson & Johnson by 0.6% in the 2nd quarter. Lenox Wealth Advisors Inc. now owns 876 shares of the company’s stock valued at $116,000 after acquiring an additional 5 shares during the period. IHT Wealth Management LLC raised its position in shares of Johnson & Johnson by 46.4% in the 2nd quarter. IHT Wealth Management LLC now owns 10,942 shares of the company’s stock valued at $122,000 after acquiring an additional 3,467 shares during the period. Finally, Mountain Capital Investment Advisors Inc acquired a new stake in shares of Johnson & Johnson in the 2nd quarter valued at approximately $124,000. Institutional investors and hedge funds own 65.70% of the company’s stock.

Shares of Johnson & Johnson (NYSE JNJ) opened at $143.97 on Thursday. Johnson & Johnson has a 52 week low of $110.76 and a 52 week high of $145.68. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.02 and a current ratio of 1.32. The stock has a market capitalization of $386,780.00, a P/E ratio of 24.99, a P/E/G ratio of 2.67 and a beta of 0.80.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, October 17th. The company reported $1.90 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.80 by $0.10. Johnson & Johnson had a return on equity of 27.38% and a net margin of 21.28%. The business had revenue of $19.65 billion during the quarter, compared to analysts’ expectations of $19.29 billion. During the same period in the prior year, the business earned $1.68 EPS. Johnson & Johnson’s revenue for the quarter was up 10.3% compared to the same quarter last year. analysts anticipate that Johnson & Johnson will post 7.28 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 13th. Investors of record on Tuesday, February 27th will be paid a dividend of $0.84 per share. The ex-dividend date of this dividend is Monday, February 26th. This represents a $3.36 dividend on an annualized basis and a yield of 2.33%. Johnson & Johnson’s payout ratio is 58.33%.

A number of brokerages recently weighed in on JNJ. Piper Jaffray Companies reiterated a “hold” rating and issued a $120.00 price target on shares of Johnson & Johnson in a research report on Wednesday, October 4th. Vetr downgraded shares of Johnson & Johnson from a “hold” rating to a “sell” rating and set a $130.49 price target on the stock. in a research report on Monday, September 18th. Stifel Nicolaus increased their price target on shares of Johnson & Johnson from $140.00 to $142.00 and gave the company a “hold” rating in a research report on Wednesday, October 18th. Wells Fargo & Co upgraded shares of Johnson & Johnson from a “market perform” rating to an “outperform” rating and increased their price target for the company from $140.00 to $149.00 in a research report on Monday, October 9th. Finally, JPMorgan Chase & Co. downgraded shares of Johnson & Johnson from an “overweight” rating to a “neutral” rating in a research report on Tuesday, January 2nd. Four equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and ten have assigned a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average target price of $145.52.

ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by Markets Daily and is owned by of Markets Daily. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The correct version of this piece of content can be accessed at https://www.themarketsdaily.com/2018/01/11/johnson-johnson-jnj-shares-sold-by-kanawha-capital-management-llc.html.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply